135 related articles for article (PubMed ID: 35673726)
1. [Expression of SOX10 and GATA3 in breast cancer and their significance].
Liu JL; Chen DS; Cheng ZQ; Hu JT
Zhonghua Bing Li Xue Za Zhi; 2022 Jun; 51(6):536-541. PubMed ID: 35673726
[No Abstract] [Full Text] [Related]
2. [Diagnostic value of combined application of GATA3, SOX10 and p16 in triple negative breast carcinomas].
Zhang DM; Zhai CJ; Feng XD; Wang CZ; Qiu JF; Wei JG
Zhonghua Yi Xue Za Zhi; 2022 Mar; 102(10):735-740. PubMed ID: 35280018
[No Abstract] [Full Text] [Related]
3. Sry-related high-mobility-group/HMG box 10 (SOX10) as a sensitive marker for triple-negative breast cancer.
Jamidi SK; Hu J; Aphivatanasiri C; Tsang JY; Poon IK; Li JJ; Chan SK; Cheung SY; Tse GM
Histopathology; 2020 Dec; 77(6):936-948. PubMed ID: 32304249
[TBL] [Abstract][Full Text] [Related]
4. Combination of GATA3, SOX-10, and PAX8 in a Comprehensive Panel to Diagnose Breast Cancer Metastases.
Na K; Woo HY; DO SI; Kim SW
In Vivo; 2022; 36(1):473-481. PubMed ID: 34972751
[TBL] [Abstract][Full Text] [Related]
5. A combination of GATA3 and SOX10 is useful for the diagnosis of metastatic triple-negative breast cancer.
Tozbikian GH; Zynger DL
Hum Pathol; 2019 Mar; 85():221-227. PubMed ID: 30468800
[TBL] [Abstract][Full Text] [Related]
6. Combined use of SOX10 and GATA3 in mammary carcinoma.
Qazi MS; McGregor SM
Pathol Res Pract; 2020 Feb; 216(2):152801. PubMed ID: 31924335
[TBL] [Abstract][Full Text] [Related]
7. TRPS1, GATA3, and SOX10 expression in triple-negative breast carcinoma.
Yoon EC; Wang G; Parkinson B; Huo L; Peng Y; Wang J; Salisbury T; Wu Y; Chen H; Albarracin CT; Resetkova E; Middleton LP; Krishnamurthy S; Gan Q; Sun H; Huang X; Shen T; Chen W; Parwani AV; Sahin AA; Li Z; Ding Q
Hum Pathol; 2022 Jul; 125():97-107. PubMed ID: 35413381
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological, immunohistochemical and molecular correlation of neural crest transcription factor SOX10 expression in triple-negative breast carcinoma.
Harbhajanka A; Chahar S; Miskimen K; Silverman P; Harris L; Williams N; Varadan V; Gilmore H
Hum Pathol; 2018 Oct; 80():163-169. PubMed ID: 29894722
[TBL] [Abstract][Full Text] [Related]
9. Combined SOX10 GATA3 is most sensitive in detecting primary and metastatic breast cancers: a comparative study of breast markers in multiple tumors.
Aphivatanasiri C; Li J; Chan R; Jamidi SK; Tsang JY; Poon IK; Shao Y; Tong J; To KF; Chan SK; Tam F; Cheung SY; Shea KH; Tse GM
Breast Cancer Res Treat; 2020 Nov; 184(1):11-21. PubMed ID: 32737715
[TBL] [Abstract][Full Text] [Related]
10. Comparative expression of TRPS1, GATA3, SOX10, mammaglobin, and GCDFP-15 in effusion specimens with breast carcinoma.
Bradt A; Jing X; Smola BS; Lew M
Diagn Cytopathol; 2023 Nov; 51(11):665-673. PubMed ID: 37461248
[TBL] [Abstract][Full Text] [Related]
11. SOX10, GATA3, GCDFP15, Androgen Receptor, and Mammaglobin for the Differential Diagnosis Between Triple-negative Breast Cancer and TTF1-negative Lung Adenocarcinoma.
Laurent E; Begueret H; Bonhomme B; Veillon R; Thumerel M; Velasco V; Brouste V; Hoppe S; Fournier M; Grellety T; MacGrogan G
Am J Surg Pathol; 2019 Mar; 43(3):293-302. PubMed ID: 30628926
[TBL] [Abstract][Full Text] [Related]
12. TRPS1 is a promising marker for all subtypes of breast cancer.
Lui JW; Tsang JY; Li J; Ko CW; Tam F; Loong TC; Tse GM
Histopathology; 2024 Apr; 84(5):822-836. PubMed ID: 38173281
[TBL] [Abstract][Full Text] [Related]
13. High frequency of p16 and SOX10 coexpression but not androgen receptor expression in triple-negative breast cancers.
Yoon EC; Wilson P; Zuo T; Pinto M; Cole K; Harigopal M
Hum Pathol; 2020 Aug; 102():13-22. PubMed ID: 32565323
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological characteristics of the SOX10+ subset of HER2+ breast cancer.
Weisman P; Yu Q; Xu J
Ann Diagn Pathol; 2023 Apr; 63():152087. PubMed ID: 36669230
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological significance of Sox10 expression in triple-negative breast carcinoma.
Jin L; Qin C; Qi X; Hong T; Yang X; Zhu X
Transl Cancer Res; 2020 Sep; 9(9):5603-5613. PubMed ID: 35117924
[TBL] [Abstract][Full Text] [Related]
16. Significantly increased PELP1 protein expression in primary and metastatic triple-negative breast carcinoma: comparison with GATA3 expression and PELP1's potential role in triple-negative breast carcinoma.
Dang DN; Raj G; Sarode V; Molberg KH; Vadlamudi RK; Peng Y
Hum Pathol; 2015 Dec; 46(12):1829-35. PubMed ID: 26428280
[TBL] [Abstract][Full Text] [Related]
17. The Added Value of SOX10 Immunohistochemistry to Other Breast Markers in Identifying Cytokeratin 5-Positive Triple Negative Breast Cancers as of Mammary Origin.
Sejben A; Vörös A; Golan A; Zombori T; Cserni G
Pathobiology; 2021; 88(3):228-233. PubMed ID: 33567441
[TBL] [Abstract][Full Text] [Related]
18. Expression patterns of GATA3 and the androgen receptor are strongly correlated in patients with triple-negative breast cancer.
Kim S; Moon BI; Lim W; Park S; Cho MS; Sung SH
Hum Pathol; 2016 Sep; 55():190-5. PubMed ID: 27184484
[TBL] [Abstract][Full Text] [Related]
19. Cytokeratin 7, GATA3, and SOX-10 is a Comprehensive Panel in Diagnosing Triple Negative Breast Cancer Brain Metastases.
Statz E; Jorns JM
Int J Surg Pathol; 2021 Aug; 29(5):470-474. PubMed ID: 33543662
[TBL] [Abstract][Full Text] [Related]
20. Predictive markers for pathological complete response after neo-adjuvant chemotherapy in triple-negative breast cancer.
Van Bockstal MR; Noel F; Guiot Y; Duhoux FP; Mazzeo F; Van Marcke C; Fellah L; Ledoux B; Berlière M; Galant C
Ann Diagn Pathol; 2020 Dec; 49():151634. PubMed ID: 32987254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
